Wednesday, March 11, 2020 10:09:26 AM
CVS was 200 a Store Product Trial not a consummated business deal. AW did not like the percentage of revenue BIEL got vs Protex the sleeve maker. Should he have gone with it anyway for the exposure, absolutely. AW is no longer making decisions at BIEL.
Dr. Scholl's was never a consummated business deal. Scholl's wanted a Licensing Deal but AW did not want to hand over the ActiPatch IP. Should he have given them the Licensing Deal, probably. AW is no longer making decisions at BIEL.
RecoveryRx, some speculated that RecoveryRx would be more profitable than ActiPatch. IMO this was never the case. Unless one has the resources of a J&J or Pfizer, to shape the sentiments of the medical community, a OTC product is always going to be a smoother path to revenue than a prescription product. RecoveryRx will find its Market and provide BIEL with revenue.
KW proved that she did not agree with AW's business decisions when she reached out to Dr. Scholl's, CVS, and KT-Tape to try and revive the deals that AW turned down.
<<<<<<< IMO, we won't see anything till all 3 deals are finalized >>>>>>
This opinion is incorrect. Dr. Scholl's and DJ Orthopedics are major established names in their Markets. Announcement of each signed Deal will increase BIEL's SP.
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM